-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
Recently, the CDE official website showed that Hengrui's SHR7280 clinical trial application was approved by the China Food and Drug Administration.
SHR7280 is a new oral small molecule gonadotropin releasing hormone receptor (GnRHR) antagonist, which can block the binding of endogenous GnRH and GnRH receptors, inhibit the synthesis and synthesis of luteinizing hormone and follicle stimulating hormone and other gonadotropins.
Previously, SHR7280 has been clinically approved by the Food and Drug Administration for two indications, namely endometriosis and prostate cancer